Brief Reports
Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions

https://doi.org/10.1067/mjd.2000.105948Get rights and content

Abstract

We treated a 57-year-old woman for refractory inflammatory bowel disease with a humanized anti–tumor necrosis factor α monoclonal antibody (Infliximab). The patient also had a 15-year history of Crohn’s disease and a 20-year history of moderate to severe psoriasis. She received a single infusion of Infliximab (5 mg/kg). Two weeks after the infusion her psoriasis had dramatically improved in appearance. To our knowledge, our case is the first reported instance of successful anti–tumor necrosis factor α therapy in psoriasis. (J Am Acad Dermatol 2000;42:829-30.)

References (5)

  • SL Gottlieb et al.

    Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis

    Nat Med

    (1995)
  • P Ettehadi et al.

    Elevated tumor necrosis factor-alpha (TNF-α) biological activity in psoriatic skin lesions

    Clin Exp Immunol

    (1994)
There are more references available in the full text version of this article.

Cited by (221)

  • Psoriasis Induced by Biological Therapy

    2021, Reumatologia Clinica
  • Tumor Necrosis Factor Inhibitors

    2020, Comprehensive Dermatologic Drug Therapy, Fourth Edition
  • Expanding the applications of microneedles in dermatology

    2019, European Journal of Pharmaceutics and Biopharmaceutics
View all citing articles on Scopus

Reprint requests: Alice B. Gottlieb, MD, PhD, Clinical Research Center, One Robert Wood Johnson Place, Box 19, New Brunswick, NJ 08903. E-mail: [email protected].

View full text